SAN CARLOS, Calif., March 12 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will participate in the following events in March and April:
Tenth Annual Lehman Brothers’ Global Healthcare Conference March 20, 2007 2:00 p.m. ET Lee Bendekgey, Senior Vice President and General Counsel http://cc.talkpoint.com/LEHM002/031907a_jw/default.asp?entity=Nuvelo CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference April 11, 2007 10:55 a.m. ET Dr. Michael Levy, Executive Vice President, Research and Development http://conferences.cibcwm.com/biotech07/
Live audio webcasts of the events and presentations will also be available online via the Investor Relations portion of Nuvelo’s website at www.nuvelo.com.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rNAPc2 which is in Phase 2 testing for potential use as a cancer therapy, as well as NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.
CONTACT: Nicole Foderaro, Director of Corporate Communications & IR ofNuvelo, Inc., +1-650-517-8472, or nfoderaro@nuvelo.com
Web site: http://www.nuvelo.com//
